Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG3421 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | po daily |
| RG3421 120mg | EXPERIMENTAL | 120mg po daily |
| RG3421 20mg | EXPERIMENTAL | 20mg po daily |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | po daily |
| RG3421 120mg | DRUG | 120mg po daily |
| RG3421 20mg | DRUG | 20mg po daily |
Inclusion Criteria: * adult patients, 18-70 years of age; * medically stable, moderate to severe chronic plaque psoriasis. Exclusion Criteria: * any skin condition which may interfere with evaluation of the effect of study medication on plaque lesions; * confounding or concomitant condition or tr...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
RG3421 is an investigational small molecule being studied for the treatment of moderate to severe chronic plaque psoriasis, a skin condition in the dermatology therapeutic area. It is not yet approved for any indication and remains in clinical development.
RG3421 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical trial evaluating the drug in patients with moderate to severe chronic plaque psoriasis.
RG3421 is in Phase 2 clinical development. The Phase 2 trial in moderate to severe chronic plaque psoriasis has been completed, and the drug is not approved for any use.
RG3421 has been evaluated in one completed Phase 2 trial, NCT00504270, titled A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis. The trial enrolled 66 patients in the United States, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.